Recommended Reading

Below is a list of apheresis literature that is useful for those practicing apheresis medicine. You are invited to submit your suggestions.

Bandarenko N, Brecher ME.
United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.
Journal of Clinical Apheresis. 1998;13(3):133-41.

Brecher ME.
Plasma exchange: why we do what we do.
Journal of Clinical Apheresis. 2002;17(4):207-11. Review.

Coppo, P., Bussel, A., Charrier, S., Adrie, C., Galicier, L., Boulanger, E., Veyradier, A., Leblanc, T., Alberti, C., Azoulay, E., Le, Gall, Jr., Schlemmer, B.
High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore). 2003;82:27.
Study demonstrating equivalency of plasma exchange and plasma infusion in TTP if equivalent volumes of plasma are given. Substantial frequency of volume overload was seen with infusion, however.

George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB.
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004 Feb;44(2):294-304. Review

George JN.
How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Blood. 2000 Aug 15;96(4):1223-9. Review

Grima KM.
Therapeutic apheresis in hematologic and oncologic diseases.
Journal of Clinical Apheresis. 2000;15:29-52.
Section in special edition.

Kale-Pradhan, P. B., Woo, M. H.
A review of the effects of plasmapheresis on drug clearance.
Pharmacotherapy. 1997;17:684.
An extensive review of the literature concerning the effects of plasma exchange on drug clearance and metobolism. The article provides suggestions for therapy modification as well as future research.

Kim HC.
Therapeutic apheresis in pediatric apheresis.
Journal of Clinical Apheresis. 2000;15:129-157.
Section in special edition.

Koo AP.
Therapeutic apheresis in autoimmune and rheumatic disease.
Journal of Clinical Apheresis. 2000;15:18-27.
Section in special edition.

McLeod BC.
Plasmapheresis in multiple sclerosis.
Journal of Clinical Apheresis. 2003;18(2):72-4.

McLeod, B. C.
Introduction to the third special issue: clinical applications of therapeutic apheresis.
Journal of Clinical Apheresis. 2000;15:1.
Includes comprehensive table listing the current ASFA categorizations of
diseases treated by apheresis.

McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, Smith JW.
Frequency of immediate adverse effects associated with therapeutic apheresis.
Transfusion. 1999 Mar;39(3):282-8.

McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW.
Frequency of immediate adverse effects associated with apheresis donation.
Transfusion. 1998 Oct;38(10):938-43.
A review of reactions occurring in a large group of apheresis donors.

[No authors listed]
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group.
Lancet. 1997 Jan 25;349(9047):225-30.

Raphael, J. C., Chevret, S., Hughes, R. A., Annane, D.
Plasma exchange for Guillain-Barre syndrome.
Cochrane Database System. 2002. Review
A comprehensive and critical review of all of the available literature concerning the effectiveness of plasma exchange in the treatment of AIDP.

Rock, G., Shumak, K. H., Sutton, D. M., Buskard, N. A., Nair, R. C.
Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.
British Journal of Haematoly. 1996;94:383.
Study of the use of cryosupernatant poor plasma in the treatment of refractory TTP.

Rock, G. A., Shumak, K. H., Buskard, N. A., Blanchette, V. S., Kelton, J. G., Nair, R. C., Spasoff, R. A.
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.
New England Journal of Medicine. 1991;325:393.
Definitive study showing superiority of plasma exchange to plasma infusion in TTP.

Shehata, N., Kouroukis, C., Kelton, J. G.
A review of randomized controlled trials using therapeutic apheresis.
Transfusion Medicine. 2002;16:200. Review
A summary of all of the randomized controlled trials involving therapeutic apheresis. Includes numerous tables summarizing the trials as well as recommendations concerning treatment protocols.

Smith JW, Weinstein R , Hillyer KL for the AABB Hemapheresis Committee.
Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis.
Transfusion. 2003 Jun;43(6):820-2.
Updated categorization of disease treated by apheresis including those categorized since the 2000 special addition as well as input from the AABB.

Zeigler, Z. R., Shadduck, R. K., Gryn, J. F., Rintels, P. B., George, J. N., Besa, E. C., Bodensteiner, D., Silver, B., Kramer, R. E.
Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP).
Journal of Clinical Apheresis. 2001;16:19.
Small randomized trial demonstrating equivalency of FFP and cyosupernatant poor plasma in primary TTP.

Weinstein R.
Therapeutic apheresis in neurological disorders.
Journal of Clinical Apheresis. 2000;15:74-128.
Section in special edition.

Winters JL, Pineda AA, McLeod BC, Grima K.
Therapeutic aphreresis in renal and metabolic diseases.
Journal of Clinical Apheresis. 2000;15:53-73.
Section of the special edition.